                         SEQUENCE LISTING

<110>  Yissum Research Development Company of the Hebrew 
       University of Jerusalem Ltd.
 
<120>  Peptides for Use in the Treatment of Viral Infections

<130>  2572744

<150>  US 62/569,295
<151>  2017-10-06

<160>  11    

<170>  PatentIn version 3.5

<210>  1
<211>  202
<212>  PRT
<213>  Homo sapiens

<400>  1

Asn Lys Ile Leu Val Lys Gln Ser Pro Met Leu Val Ala Tyr Asp Asn 
1               5                   10                  15      


Ala Val Asn Leu Ser Cys Lys Tyr Ser Tyr Asn Leu Phe Ser Arg Glu 
            20                  25                  30          


Phe Arg Ala Ser Leu His Lys Gly Leu Asp Ser Ala Val Glu Val Cys 
        35                  40                  45              


Val Val Tyr Gly Asn Tyr Ser Gln Gln Leu Gln Val Tyr Ser Lys Thr 
    50                  55                  60                  


Gly Phe Asn Cys Asp Gly Lys Leu Gly Asn Glu Ser Val Thr Phe Tyr 
65                  70                  75                  80  


Leu Gln Asn Leu Tyr Val Asn Gln Thr Asp Ile Tyr Phe Cys Lys Ile 
                85                  90                  95      


Glu Val Met Tyr Pro Pro Pro Tyr Leu Asp Asn Glu Lys Ser Asn Gly 
            100                 105                 110         


Thr Ile Ile His Val Lys Gly Lys His Leu Cys Pro Ser Pro Leu Phe 
        115                 120                 125             


Pro Gly Pro Ser Lys Pro Phe Trp Val Leu Val Val Val Gly Gly Val 
    130                 135                 140                 


Leu Ala Cys Tyr Ser Leu Leu Val Thr Val Ala Phe Ile Ile Phe Trp 
145                 150                 155                 160 


Val Arg Ser Lys Arg Ser Arg Leu Leu His Ser Asp Tyr Met Asn Met 
                165                 170                 175     


Thr Pro Arg Arg Pro Gly Pro Thr Arg Lys His Tyr Gln Pro Tyr Ala 
            180                 185                 190         


Pro Pro Arg Asp Phe Ala Ala Tyr Arg Ser 
        195                 200         


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  p2TA core sequence

<400>  2

Ser Pro Met Leu Val Ala Tyr Asp 
1               5               


<210>  3
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  p1TA core sequence

<400>  3

His Val Lys Gly Lys His Leu Cys Pro 
1               5                   


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  p3TA core sequence

<400>  4

His Lys Gly Leu Asp Ser Ala Val 
1               5               


<210>  5
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  p4TA core sequence

<400>  5

Tyr Val Asn Gln Thr Asp Ile Tyr 
1               5               


<210>  6
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  p5TA core sequence

<400>  6

Ser Asn Gly Thr Ile Ile His Val Lys 
1               5                   


<210>  7
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (D-A)-p2TA-(D-A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X equals to D-Ala

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X equals to D-Ala

<400>  7

Xaa Ser Pro Met Leu Val Ala Tyr Asp Xaa 
1               5                   10  


<210>  8
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (D-A)-p1TA-(D-A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X equals to D-Ala

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X equals to D-Ala

<400>  8

Xaa His Val Lys Gly Lys His Leu Cys Pro Xaa 
1               5                   10      


<210>  9
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (D-A)-p3TA-(D-A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X equals to D-Ala

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X equals to D-Ala

<400>  9

Xaa His Lys Gly Leu Asp Ser Ala Val Xaa 
1               5                   10  


<210>  10
<211>  10
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (D-A)-p4TA-(D-A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X equals to D-Ala

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  X equals to D-Ala

<400>  10

Xaa Tyr Val Asn Gln Thr Asp Ile Tyr Xaa 
1               5                   10  


<210>  11
<211>  11
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  (D-A)-p5TA-(D-A)


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  X equals to D-Ala

<220>
<221>  MISC_FEATURE
<222>  (11)..(11)
<223>  X equals to D-Ala

<400>  11

Xaa Ser Asn Gly Thr Ile Ile His Val Lys Xaa 
1               5                   10      


